The lane and the lead time matter as much as the material for what I am doing.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
The short version: real savings on carriage and unit price, real risks in custody, splitting and the legal position of whoever receives it.
Whoever receives the consignment is the importer of record in most jurisdictions, regardless of who paid. That is a legal position rather than an administrative one and it does not divide among contributors.
| Step | Value | Note |
|---|---|---|
| Vial price, 10 mg nominal | £34.00 | As advertised |
| Nominal cost per mg | £3.40 | 34 ÷ 10 |
| Measured content | 9.2 mg | Independent content assay |
| Cost per actual mg | £3.70 | 34 ÷ 9.2 |
| Dead-space loss, 20 draws | 4 % | 80 µL of a 2 mL fill |
| Cost per delivered mg | £3.85 | 3.70 ÷ 0.96 |
| First vial, with £110 assay | £14.85 | Testing dominates a single vial |
Keep a written record: who contributed, what was ordered, which lot arrived, how many vials each person received and when. It resolves disputes and it is the only documentation that will exist.
Carriage costs on international consignments scale far less than linearly with weight, which is the arithmetic basis for the saving.
Start small even with several people. Especially with several people.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsTo be exact about it, this is one of the areas where the practical advice is mostly about structure rather than about chemistry.
The real saving is in carriage and in unit price breaks, not in the compound itself. Carriage on a single larger consignment is typically a fraction of the sum of individual shipments, and that is where most of the arithmetic comes from.
Mechanically, splitting sealed vials preserves the manufacturer's container closure and the lot traceability. Splitting anything that has been opened, reconstituted or repackaged breaks both and no certificate follows the material after that point.
Importer-of-record status attaches to the receiving party in most customs regimes and is not divisible among contributors.
One lot for the group means one submission covers everybody. That is the real advantage.
Answer first: the economics work and the counterparty risk is the whole problem, because a group buy concentrates money and material in one person's hands.
Ordering a single lot for the whole group is the analytical advantage: one independent submission then characterises everyone's material, which spreads the cost of testing across the participants.
Custody is the risk. One person holds the money before the order and the material after it, and there is no mechanism to compel anything if it goes wrong.
The caveat is legal rather than analytical: onward supply is treated differently from personal importation in many jurisdictions and the difference is not a technicality.
Whoever receives it is the importer. Make sure that person knows.
edited 6 Aug 2024 by w_okoye — corrected a unit error in the worked example
The relevant point is that whoever receives the consignment is the importer, with whatever that means in their jurisdiction.
A first group order should be small for the same reason a first individual order should be, and the argument is stronger rather than weaker when several people are exposed.
Container closure integrity is what makes a lot-specific certificate meaningful for a specific vial; breaking it severs the link between document and material.
Write down who paid what and who received what, before it ships.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.